Innocoll   Report issue

For profit Phase 2 Phase 3
Founded: Ashburn Virginia United States (1985)
Status: No NME R&D (1985)

Organization Overview

First Clinical Trial
2007
NCT00624910
First Marketed Drug
2020
levobupivacaine (chirocaine)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Innocoll | INNOCOLL | INNOCOLL PHARMS | Vice President, Global Clinical Operations, Innocoll Pharmaceutical | Vice President, Global Clinical Operations, Innocoll Pharmaceuticals

Active Ingredients

Marketed Drugs (1)

levobupivacaine (chirocaine) (2020)

Drugs in Phase 3 Trials (4)

bupivacaine (Exparel) (5 trials)

collagen (7 trials)

gentamicin (garamycin) (7 trials)

levobupivacaine (chirocaine) (6 trials)

Drugs in Phase 2 Trials (1)

levofloxacin (levaquin) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Diabetic Foot (Phase 3)

Foot Ulcer (Phase 3)

Hernia (Phase 3)

Hernia, Inguinal (Phase 3)

Infections (Phase 3)

Pain, Postoperative (Phase 3)

Surgical Wound (Phase 3)

Surgical Wound Infection (Phase 3)

Ulcer (Phase 3)

Wound Infection (Phase 3)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial APIs: 5